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Abstract: As synthetic analogs of the natural pigment melanin, polydopamine nanoparticles (NPs) are
under active investigation as non-toxic anticancer photothermal agents and as free radical scavenging
therapeutics. By analogy to the widely adopted polydopamine coatings, polydopamine NPs offer
the potential for facile aqueous synthesis and incorporation of (bio)functional groups under mild
temperature and pH conditions. However, clear procedures for the convenient and reproducible
control of critical NP properties such as particle diameter, surface charge, and loading with functional
molecules have yet to be established. In this work, we have synthesized polydopamine-based
melanin-mimetic nanoparticles (MMNPs) with finely controlled diameters spanning ≈25 to 120 nm
and report on the pH-dependence of zeta potential, methodologies for PEGylation, and the
incorporation of fluorescent organic molecules. A comprehensive suite of complementary techniques,
including dynamic light scattering (DLS), cryogenic transmission electron microscopy (cryo-TEM),
X-ray photoelectron spectroscopy (XPS), zeta-potential, ultraviolet–visible (UV–Vis) absorption and
fluorescence spectroscopy, and confocal microscopy, was used to characterize the MMNPs and their
properties. Our PEGylated MMNPs are highly stable in both phosphate-buffered saline (PBS) and in
cell culture media and exhibit no cytotoxicity up to at least 100 µg mL−1 concentrations. We also show
that a post-functionalization methodology for fluorophore loading is especially suitable for producing
MMNPs with stable fluorescence and significantly narrower emission profiles than previous reports,
suggesting they will be useful for multimodal cell imaging. Our results pave the way towards
biomedical imaging and possibly drug delivery applications, as well as fundamental studies of
MMNP size and surface chemistry dependent cellular interactions.
Keywords: catechol; melanin; nanoparticle; dopamine
1. Introduction
Nanotechnology has garnered tremendous attention from the biomedical community over the
past decade due to its potential to revolutionize cancer treatment by delivering targeted packages of
chemotherapeutic drugs, thereby minimizing their adverse side-effects and boosting bioavailability [1–8].
Despite intense research, however, few nanotechnology-based solutions are clinically-approved as
Biomimetics 2017, 2, 17; doi:10.3390/biomimetics2030017 www.mdpi.com/journal/biomimetics
Biomimetics 2017, 2, 17 2 of 19
cancer therapeutics [8,9]. An improved understanding of nanoparticle–cell and nanoparticle–body
interactions is essential for the optimization of nanoparticle (NP) design to improve therapeutic
outcomes. Fluorescent NPs enable in-depth study of these phenomena, as illustrated in the recent
use of quantum dots (QDs) by Chan et al. to study the fundamental mechanisms of hard NP
clearance by the liver [10]. Improving the design of organic NP-based therapeutics requires study of
soft organic NPs rather than hard inorganic NPs like QDs, spurring interest in fluorescent organic
NPs (FONs) [11,12]. A variety of approaches including emulsion polymerization, block copolymer
self-assembly, and nanoprecipitation in the presence of a fluorophore have been employed in the
synthesis of FONs [11,12]. However, many FON synthesis techniques require the use of toxic organic
solvents or surfactants, which must be removed following synthesis.
The recent development of polydopamine melanin-like NPs has created an opportunity to
generate organic NPs in a non-toxic, straightforward strategy. Inspired by the presence of sepia
melanin NPs in cuttlefish ink, Ju et al. first reported a synthesis of non-toxic melanin-like NPs
composed of polydopamine [13]. Nanoparticles were prepared by dissolving dopamine·HCl in water
at basic pH to generate polydopamine NPs, which had melanin-like free radical scavenging activity.
Although the exact mechanism and species involved in the formation of polydopamine are still actively
under investigation, there is mounting experimental and computational evidence that polydopamine
forms via oxidation of dopamine, producing a complex series of subsequent reactions that are not
fully understood [14,15]. This material has properties similar to the biological pigment eumelanin,
which has functions including protection against harmful ultraviolet (UV) light, free radical scavenging,
heavy metal sequestration, and structural roles, as in the Glycera dibranchiata bloodworm jaw [16–19].
One unique property of polydopamine is its chemical versatility. Studies on polydopamine
surface coatings have shown that it can subsequently be modified via covalent bonding with amines
and thiols, hydrogen bonding, pi–pi stacking, metal coordination, and electrostatic interactions [20,21].
This characteristic of polydopamine may be leveraged to form multifunctional polydopamine-based
melanin-mimetic NPs (MMNPs) for biomedical applications without the use of coupling reagents or
biomolecular modification, unlike many existing fluorescent NP systems [11,12,22].
Since the initial synthesis of MMNPs by Ju et al. [13], alternate methods of creating MMNPs
have also been developed [23,24]. Polydopamine NPs have shown promising results when studied
as melanin-like UV-protective materials in cells [25], anticancer photothermal agents in vivo [23],
and as magnetic resonance imaging (MRI) contrast agents [26]. Despite these reports, neither the
reproducibility of NP size control over a broad range of sub-200 nm diameters nor the NP surface
charge have yet been studied in depth.
Related work has focused on synthesis of fluorescent microcapsules or plate-like nanostructures
of polydopamine via oxidation by H2O2 [26–28] or by combination of polyethyleneimine and
polydopamine [29,30]. These novel nanomaterials have promise as potential fluorescent organic
NPs or microparticles, but they possess several shortcomings. First, the sizes and morphologies
of these fluorescent materials limit conclusions that could be drawn with regard to the uptake and
trafficking of spherical NPs with diameters below 100–200 nm, which is the most relevant size ranges
for injectable nanotherapeutics. Second, each of these published methods of fluorescent polydopamine
preparation results in broad fluorescence excitation and emission spectral peaks that may interfere
with dyes to be used as co-stains for in vitro studies. Full-width half maximum (FWHM) of the peaks
in these studies are on the order of 100 nm, limiting simultaneous use of other fluorophores. In contrast,
quantum dots have spectral linewidths of just 12 nm [31]. Third, fluorescence excitation and emission
peaks cannot be tuned using this approach. Modification of NPs with different fluorophores would
permit this fine-tuning. We sought to address these three issues through our research.
In this work, we demonstrate a novel, straightforward method by which MMNPs with
reproducibly tunable diameters under 100–200 nm can be synthesized and modified by two
fluorescent rhodamine dyes, rhodamine 123 (RA123) and rhodamine B (RAB). We have developed
procedures by which MMNPs may be rhodamine-labeled either in situ during MMNP formation or by
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post-functionalization of PEGylated MMNPs. Neither of these methods require any toxic or expensive
chemical coupling reagents, organic solvents, surfactants, or oxidizing agents. We demonstrate that
these materials have narrower fluorescence excitation and emission peaks (FWHM ≈40 nm) relative
to other methods of fluorescent polydopamine NP preparation. As a proof of concept, we show
that PEGylated fluorescent MMNPs are taken up by cells and accumulate in the perinuclear region,
where they can be visualized by confocal microscopy.
2. Materials and Methods
2.1. Materials
Dopamine·HCl (DA, >98% purity), rhodamine 123 (RA123), and rhodamine B base (RAB) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Methyl ether poly(ethylene glycol)-thiol
(5 kDa, mPEG-SH) was purchased from Laysan Bio, Inc. (Arab, AL, USA). Neutral red dye was
purchased from Amresco (Solon, OH, USA). Ultrapure (UP) water was obtained by purification of
deionized water with a Barnstead Ultrapure Water Purification System (Thermo Fisher Scientific,
Waltham, MA, USA) to a resistivity of at least 18.0 MΩ cm. Amicon®Ultra centrifugal filters
with 10 kDa and 100 kDa molecular weight cut-off (MWCO) were obtained from EMD Millipore
(Billerica, MA, USA). Dialysis cassettes (10 kDa MWCO) and cell culture reagents were obtained
from Thermo Fisher Scientific. NIH/3T3 fibroblasts were purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA).
2.2. Nanoparticle Synthesis and Modification
2.2.1. MMNP Synthesis
Melanin-mimetic nanoparticle synthesis was adapted from Ju et al. [13]. For a typical synthesis
(1:1 NaOH:DA, 1 mgmL−1 DA), 22.68mL of UPwater and 1.32mL of 0.1MNaOHwere added to a 50mL
round bottom flask and heated to 50 ◦C under vigorous stirring. Then, 1 mL of a 25 mgmL−1 DA solution
was added. The flask was tightly capped, and the solution was vigorously stirred for 5 h at 50 ◦C.
After 5 h, the reaction mixture was purified by centrifugal filtration (10 kDa MWCO), washing with
UP water. Then, aggregates were removed by centrifugation at between 2000 and 6000 g followed
by 0.45 µm filtration. The hydrodynamic diameters (Dh) of MMNPs were adjusted by controlling
DA concentration (1 to 4 mg mL−1) and NaOH:DA molar ratio (0.5:1 to 1:1).
2.2.2. In Situ Modification of MMNPs with Rhodamine B or Rhodamine 123
For in situ fluorophore modification, MMNPs synthesis was performed as noted above in a growth
solution of 1 mg mL−1 DA and 1:1 NaOH:DA supplemented with 50 µg mL−1 RAB or RA123.
2.2.3. PEGylation of MMNPs
Melanin-mimetic nanoparticles were treated with 10 mM 5 kDa mPEG-SH overnight in
10 mM NaOH. Unbound mPEG-SH was removed by centrifugal filtration (100 kDa MWCO) at
2000× gwith washing.
2.2.4. Post-Functionalization of MMNP@PEG with Rhodamine B or Rhodamine 123
Purified MMNP@PEG were post-functionalized for 24 h with RAB or RA123 in either UP water
or aqueous pH 8.5 bicine buffer containing 40 µg mL−1 MMNP@PEG and 50 µg mL−1 RA123 or RAB.
The post-functionalized NPs (MMNP@PEG@RAB and MMNP@PEG@RA123) were initially purified
by at least six rounds of centrifugal filtration (100 kDa MWCO) with washing to remove unbound
fluorophore. Nanoparticles were dialyzed (10 kDa MWCO) for four days in UP water before use in
cell culture, replacing the dialysis bath at least five times.
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2.2.5. Fluorophore Release Testing
In order to evaluate the release of fluorophore, 50–100 µg fluorophore-labeled MMNPs
were dialyzed (10 kDa MWCO) in 200 mL UP water or 1× phosphate-buffered saline
(PBS). MMNP@RA123@PEG and MMNP@RAB@PEG were dialyzed for seven days in PBS,
and MMNP@PEG@RA123 and MMNP@PEG@RAB were dialyzed sequentially in UP water for
three days and in 1× PBS for three days. The dialysis baths were replaced every 4–6 h for the
first 12 h to preserve sink conditions and at least every 24 h for the next several days. Fluorophore
release was quantified by measuring fluorescence of aliquots of the dialysis baths (Tecan Infinite M200,
Männendorf, Switzerland) and quantifying fluorophore content using standard curves prepared from
RA123 and RAB stock solutions.
2.3. Nanoparticle Characterization
2.3.1. Extinction Coefficient Calculation
An ultraviolet–visible (UV–Vis) plate reader (Synergy H1, BioTek, Winooski, VT, USA) was used
to determine absorbances of solutions with known concentrations of MMNPs at wavelengths from
300 to 1000 nm. At least three batches of MMNPs from each set of synthesis conditions was used to
calculate the extinction coefficients. Initial concentration of MMNPs was calculated by lyophilizing
1 mL suspensions of MMNPs. Exponential decay curves were fit to extinction coefficient data using
OriginPro 2017 software (Student version, OriginLab, Northampton, MA, USA).
2.3.2. Dynamic Light Scattering and Zeta Potential Analysis
Dynamic light scattering (DLS) and zeta potential analysis of NPs was conducted using a Malvern
Zetasizer Nano ZS instrument (Malvern, Worcestershire, UK). The z-average NP diameters of NP batches
were calculated using cumulants analysis andwas reported as theDh. The polydispersity index (PDI) was
also measured by DLS. During zeta potential measurements, pH was controlled during measurements
by using 10 mM citrate buffer (pH 2.5–6.5), 10 mMN-2-hydroxyethylpiperazine-N-2-ethane sulfonic
acid (HEPES) buffer (pH 7.0–7.5), or 10 mM bicine buffer (pH 8.0–9.0). Unless otherwise noted,
zeta potential was measured at pH 7.4. At least three independently prepared batches of NPs were
used for every reported Dh or zeta potential value.
2.3.3. Electron Microscopy Imaging
Scanning electron microscopy (SEM) images were obtained using an FEI Quanta 3D FEG SEM
(Hillsboro, OR, USA). Conventional transmission electron microscopy (TEM) imaging was performed
on a JEOL 1400 TEM (Tokyo, Japan) or FEI Tecnai 12 TEM (Hillsboro, OR, USA). Samples were
prepared either with or without uranyl acetate staining. Cryogenic TEM (cryo-TEM) imaging was
performed using a JEOL 1230 TEM (Tokyo, Japan). Nanoparticle size analysis was performed using
ImageJ software [32] to measure diameters of at least 35 NPs from representative cryo-TEM images of
each size range. All NPs in representative images were included in size analysis.
2.3.4. Spectroscopic Characterization
Fluorescence spectra of fluorescent NPs, fluorophores, and unmodified MMNPs were taken using
a FluoroMax-4 spectrophotometer (Horiba Scientific, Irvine, CA, USA) with 5 nm slit widths. Samples
containingRA123 andRA123were excited at λex = 500 nm, and those containingRABandRABwere excited
at λex = 555 nm. The UV–Vis absorbance spectra were taken using a PerkinElmer Lambda UV/Vis/NIR
(Waltham, MA, USA) or a UV2600 spectrophotometer (Shimadzu Scientific Instruments, Kyoto, Japan).
Fluorescent spectra were not normalized, but absorbance spectra were normalized by multiplying
each curve by a constant factor.
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2.3.5. X-ray Photoelectron Spectroscopy Characterization
Gold-coated silicon substrates were first cleaned by sonication in UP water, acetone,
and isopropanol for 10 min each. Then, after drying them with a flow of nitrogen, the substrates were
exposed to a plasma discharge at 60 W for 10 min (Harrick Plasma Cleaner, Ithaca, NY, USA). A 50 µL
drop of each NP suspension was then placed onto the surface of the substrates and left to dry overnight.
Substrates were completely dried under vacuum prior to analysis using a PHI 5600 spectrometer
(PerkinElmer) equipped with an Al monochromated 2 mm filament and a built-in charge neutralizer.
The X-ray source operated at 350 W, 14.8 V, and 40◦ take-off angle. The atomic concentrations of
sulfur, nitrogen, oxygen, and carbon of drop-casted MMNP and MMNP@PEG samples by performing
survey scans between 0 and 1100 eV electron binding energies. Charge correction was performed
setting the C 1s peak at 285.0 eV. Data analysis was conducted using MultiPak software version 9.6.015
(Physical Electronics, Chanhassen, MN, USA).
2.4. In Vitro Uptake and Cytocompatibility Evaluation
2.4.1. MMNP@PEG Cytocompatibility Study
The procedure used for MMNP@PEG cytocompatibility quantification by neutral red uptake was
adapted from Repetto et al. [33]. NIH/3T3 fibroblasts were seeded onto a 96-well plate (10,000 cells/well)
and incubated overnight in Dulbecco's Modified Eagle's medium (DMEM, Life Technologies Corporation,
Carlsbad, CA, USA) supplemented with 5% newborn calf serum (NBCS, Fisher Scientific,
Chicago, IL, USA) and 1% penicillin/streptomycin (Life Technologies Corporation). The cell media
were then removed, and 0.2 µm filtered 42, 83, and 146 nm diameter MMNP@PEG samples were
introduced to the wells in DMEM supplemented with 5% NBCS with penicillin/streptomycin. Dead
cell control wells were treated with 0.2 mg mL−1 sodium lauryl sulfate-containing media, and live cell
control wells were treated with media without MMNP@PEG. Each treatment was performed in three
wells. After incubating the fibroblasts with MMNP@PEG for 24 h, cell media were removed from all
wells, and the cells were rinsed with PBS. A 40 µg mL−1 neutral red solution was added to the wells
in DMEM, and the cells were incubated for 3 h. The DMEMwas then aspirated off the cells, and the
cells were rinsed with PBS. Subsequently, a solution of 50% ethanol/49% UP water/1% glacial acetic
acid was added to the wells. The absorbance of each well was read at λabs = 540 nm in a plate reader
(Synergy H1, BioTek). The data were normalized as follows:
Relative Cell Viability =
OD540treated −OD540dead
OD540untreated
(1)
OD540treated represents the optical density of treated cells at 540 nm, OD540dead represents
the optical density of dead control cells killed with 0.2 mg mL−1 sodium lauryl sulfate at 540 nm,
and OD540untreated represents the optical density of live control cells treated with MMNP@PEG-free
media at 540 nm. The OD540 of live cells treated with MMNP@PEG without neutral red was negligible
following the PBS rinse step, obviating the need to correct OD540 of neutral red-treated cells further.
2.4.2. MMNP@PEG@RA123 Uptake Study
NIH/3T3 fibroblasts were seeded onto 35 mm tissue culture dishes (FluoroDish, World Precision
Instruments, Sarasota, FL, USA) and incubated for 24 h with 0.2 µm filtered 20 µg mL−1
MMNP@PEG@RA123 in DMEM supplemented with 10% fetal bovine serum (FBS, Life Technologies)
and 1% penicillin/streptomycin. MMNP@PEG@RA123 were prepared by post-functionalization
of MMNP@PEG with RA123 in water. The cells were then rinsed with PBS and treated with
Hoechst nuclear stain (Life Technologies). Standard and z-stack images of the live cells were taken
using a Zeiss LSM 510 inverted confocal microscope (Carl Zeiss AG, Oberkochen, Germany).
Hoechst staining was observed at λem = 410 nm and two-photon excitation (λex = 760 nm),
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and MMNP@PEG@RA123 were visualized using λem = 525 nm and λex = 488 nm. z-Stack images
were taken with slices spaced evenly over 8–15 µm z-stack heights. Images were processed using
ZEN 2.3 Lite software (Blue edition, Carl Zeiss Microscopy GmbH, Munich, Germany).
2.5. Statistical Analysis
Statistical analysis was performed in Minitab 17 (Minitab Inc., State College, PA, USA) by
conducting analysis of variance (ANOVA) followed by post-hoc Tukey tests. Error bars in figures
represent standard deviations (SD) or standard errors as specified.
3. Results and Discussion
3.1. MMNP Formation via Dopamine Autoxidation, Comparisons with Melanin, and Characterization of
Surface Charge
After adding DA to aqueous NaOH, the solution gradually changed from colorless to yellow to
dark brown-black within one hour. The purified MMNP suspension was black and demonstrated
a smooth, monotonically decaying broadband UV–Vis absorbance like melanin, with highest
absorbance in the UV region (Figure 1a). In contrast, measurements of the supernatant solution
removed during growth show absorbance peaks at 280 and 398 nm superimposed upon this
monotonically decaying curve. These peaks have been attributed to the (precursor) DA monomer and
its oxidation product dopamine o-quinone, respectively. Since no oxidant was added to the growth
solution except for ambient dissolved oxygen, the presence of both DA and dopamine o-quinone in the
solution phase confirm that MMNP formation follows an autoxidation route [34,35]. The monotonically
decaying UV–Vis absorbance in both the filtrate and pure MMNP spectra are consistent with the
formation of polydopamine, some of which may be present as pre-formed oligomers below 10 kDa in
the raw product (ibid.).
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Figure 1. Ultraviolet–visible (UV–Vis) absorbance and surface charge of polydopamine-based
melanin-mimetic nanoparticles (MMNPs). (a) UV-Vis spectra of purified MMNPs and filtrate removed
from crude product via 10 kDa centrifugal filtration. Arrows in (a) indicate the two peaks observed at
280 and 398 nm in the filtrate absorbance spectrum that are absent in the purified MMNP absorbance
spectrum. A.U.: Arbitrary units. (b) Zeta potential of MMNPs at pH 2.5–9.0. The isoelectric point is
approximately pH 4.0–4.1.
For each synthetic condition, MMNP extinction coefficients were calculated at wavelengths
from 300 to 1000 nm (Supplementary Figure S1). The fit of these coefficients to a single exponential
decay function of wavelength was excellent (r2 > 0.998; Supplementary Figure S1 and Table S1).
Notably, these extinction coefficients match closely with values reported by Sarna et al. for melanin,
especially for MMNPs with Dh < 50 nm (Supplementary Figure S1) [36,37]. These calculated extinction
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coefficients enabled rapid quantification of MMNP concentrations in our study and could be used
in future work. Finally, we investigated the surface charge of MMNPs as a function of pH between
pH 2.5 and 9.0 (Figure 1b) to determine the potential role of electrostatic interactions in MMNP surface
loading (see Sections 3.3–3.5). An isoelectric point of approximately pH 4.0–4.1 was observed, which is
in agreement with previous findings on polydopamine films [38]. X-ray photoelectron spectroscopy
data also shows a carbon to oxygen ratio of the MMNPs that is essentially identical with polydopamine
(see Section 3.3).
The chemical similarity of the MMNPs and polydopamine coatings indicates that common
methods of polydopamine functionalization may be applied to the MMNPs. Moreover, the clear trend
in surface ionization of MMNPs with pH suggests that electrostatic attraction may be utilized for
MMNP modification in a pH-dependent manner (see Section 3.5).
3.2. MMNP Size Control
By varying the DA concentration (1 to 4 mg mL−1) and NaOH:DA molar ratio (0.5:1 to 1:1) in
the synthesis of MMNPs, nanoparticle Dh could be adjusted from 28 to 117 nm. Figure 2 shows the
diameters of MMNPs as measured by DLS. Highly reproducible results were obtained by our synthetic
methodology. All reported results represent the average of at least three (and up to 19) independent
sample preparations.
Note that the commercially available DA is an HCl salt, and the NaOH serves to neutralize
this salt as well as to increase the pH to facilitate polydopamine formation. Second, increasing DA
concentration at constant NaOH:DA molar ratio resulted in larger NPs (Figure 2a and Supplementary
Figure S2). Holding the NaOH:DA ratio constant at 1:1, increasing DA from 1 to 2 mg mL−1 resulted in
an increase of Dh from 28.1 ± 8.8 nm to 49.5 ± 12.3 nm (mean ± SD). We attribute this to the increased
quantity of dopamine available to bind to each nucleated NP. These trends demonstrate significantly
finer control of NP diameter over the sub-100 nm scale compared to previous attempts to control
MMNP sizes [13].
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Figure 2. Dynamic light scattering (DLS) analysis of MMNPs. (a) Mean hydrodynamic diameters and
(b) polydispersity indices (PDI) of multiple batches of MMNPs prepared at various dopamine·HCl (DA)
concentrations and NaOH:DA ratios. n = 3−19 independently prepared batches of MMNPs were
analyzed for each synthetic condition. Error bars represent standard deviations. Bars not sharing
symbols in (a) differ significantly with p < 0.001.
Although the average Dh values were highly consistent from batch to batch, this consistency must
be distinguished from the variance in MMNP diameter within each batch, which was assessed initially
by PDI. The average PDI of NP batches prepared at each condition ranged from 0.09 to 0.25 (Figure 2b).
This result indicates that individual MMNP batches are relatively monodisperse for organic NPs but
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that size analysis beyond cumulants analysis of DLS data is required [39]. As such, the polydispersity
and morphology of MMNPs were further assessed by SEM, TEM, and cryo-TEM (Figure 3; see also
Supplementary Figures S3 and S4, and Table S2). Spherical NPs were always observed. The imaging
data also corroborate the DLS data demonstrating that NP size increased as DA concentration increased
and as NaOH:DA ratio decreased (Figure 3).
Unimodal size distributions were observed for synthesis conditions that produced MMNPs up
to a diameter of ≈50 to 60 nm (Figure 3). Minimal MMNP aggregation was observed in images
obtained by cryo-TEM, which does not suffer from the drying artifacts of conventional TEM and SEM,
confirming that the products mainly consisted of dispersed NPs. In particular, low polydispersities
were obtained for MMNPs produced both at 1 mg mL−1 and 2 mg mL−1 DA with 1:1 NaOH:DA
(SD of 9.1 nm and 12.4 nm were observed, respectively; Figure 3h,i and Supplementary Table S2).
However, the NP size distribution was bimodal at 2 mg mL−1 DA with only 0.8:1 NaOH (Figure 3g),
with distinct NP populations centering around Dh = 65 nm and 100 nm. Because the DLS signal
intensity is related to the 6th power of the particle diameter (i.e., weighted more heavily toward the
larger nanoparticles), this cryo-TEM result is consistent with the DLS data shown in Figure 2 indicating
an average Dh = 120 nm at this condition.
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Figure 3. Transmission electron microscopy (TEM) images of MMNPs and quantitative analysis of
nanoparticle diameter grown at the conditions specified at the top of each column. (a–c) TEM images
with uranyl acetate negative stain. (d–f) Cryo-TEM images were taken without staining. Nanoparticles
are spherical but have rougher appearances as diameter decreases. (g–i) Distribution of MMNP
diameters in cryo-TEM images.
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3.3. PEGylation to Produce MMNP@PEG
We focused on the 49.5 nm MMNPs for PEGylation studies because these NPs would remain
within a biologically useful size regime following modification (i.e., Dh <100 nm). PEGylation was
achieved by overnight treatment with 10 mM 5 kDa mPEG-SH in 10 mMNaOH, and the NPs were
evaluated using zeta potential, DLS, and XPS data. Control batches of MMNPs were treated with
10 mM NaOH base without mPEG-SH.
The zeta potential of the resulting MMNP@PEG was −20.9 ± 0.5 mV at pH 7.4, which was
significantly higher than those of both untreated MMNPs (−32.5 ± 0.1 mV) and base treated MMNPs
(-33.8 ± 1.0 mV) at pH 7.4 (Figure 4a), indicating shielding of the negatively charged polydopamine
MMNP surface. Consistent with the zeta potential results, DLS shows PEGylation increased the
Dh of the MMNPs by 24 nm to 71.5 ± 1.1 nm (Figure 4b). Melanin-mimetic nanoparticles treated
with base alone did not have a significantly greater Dh than untreated MMNPs, confirming that
the NP diameter increase was not caused by MMNP growth or aggregation in basic conditions.
Additionally, TEM imaging shows that MMNP@PEG have spherical morphology similar to that of
MMNPs (Figure 4c), validating the use of the standard spherical NP analysis of the DLS data.
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Figure 4. MMNP@PEG vs. MMNP zeta potential, hydrodynamic diameter, morphology, and atomic
composition. (a) Zeta potentials and (b) hydrodynamic diameters of MMNPs, MMNP@PEG, and control
MMNPs treatedwith 10mMNaOH base. Samples not sharing symbols are significantly different (p < 0.05).
(c) TEM image of MMNP@PEG. (d) XPS survey scans of MMNP andMMNP@PEG with assignments for
O 1s, N 1s, C 1s, and S 2s, and S 2p peaks. (e) C/O atomic ratios in MMNP vs. MMNP@PEG calculated
from C 1s and O 1s signal ratios (* p < 0.01). at%: Atomic percent relative to total C, N, O, and S
content. (f) Sulfur content in MMNP vs. MMNP@PEG calculated from S 2p signal intensity expressed
as at% S (* p < 0.01). Error bars represent standard errors.
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The thickness of the PEG layer is 12 nm (half of the change in Dh), twice the thickness that
would be expected from the mushroom regime [40,41], providing evidence that PEG is packed
in the brush regime rather than the mushroom regime at the surface of MMNPs. A PEG brush
causing a similar diameter increase has also been reported previously to provide sufficient resistance
against protein adsorption and phagocytosis on other organic and inorganic NP cores, including
poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), and gold [42–47].
PEGylation was further corroborated by XPS analysis of drop-casted NPs suspensions (Figure 4d).
In addition to O 1s, N 1s, and C 1s signals, the survey spectrum of MMNP@PEG reveals the
presence S 2s and S 2p signals, indicating the presence of sulfur from mPEG-SH. Sulfur peaks
were absent in unmodified MMNP controls. Moreover, the C/O atomic ratios decreased from
4.12 ± 0.01 for unfunctionalizedMMNP controls to 2.82± 0.03 for MMNP@PEG. Since MMNP@PEG is
compositionally a mixture of polydopamine and PEG, this latter C/O ratio is consistent with successful
PEGylation because it is intermediate between the theoretical ratio of 4 for dopamine and its oxidation
products and a ratio of 2 for mPEG-SH. Furthermore, while high resolution C 1s and O 1s spectra
for MMNPs show pi–pi*, C=O, C–O/C–N, C–Hx/C–C chemical shifts corresponding to previously
reported polydopamine coatings (Supplementary Figure S5) [48,49], the spectra of MMNP@PEG show
large increases of C–O components, demonstrating the presence of PEG on the MMNP@PEG.
3.4. Stability of MMNP@PEG
The stabilities of MMNP and MMNP@PEG samples were compared by immersion in 1× PBS
and in cell culture media (DMEM + 10% serum) for 24 h. Before PEGylation, MMNPs were stable in
UP water but aggregated in 1× PBS (Supplementary Figure S6a). Thus, the electrostatic repulsion
between unfunctionalized MMNPs was insufficient in maintaining colloidal stability with screening
at physiologic ionic strength. Incidentally, in cell culture media with serum, MMNPs do not visibly
aggregate and appeared to be stable (Supplementary Figure S6b). Potentially, this effect is due to the
sterically stabilizing effect of serum proteins bound to the polydopamine surface of MMNPs, as it is
known that amine groups in proteins can covalently bind to the polydopamine surfaces at physiologic
pH [50]. In contrast, MMNP@PEG remained stable for 24 h in both 1× PBS and cell culture media
(Supplementary Figure S6c,d). Even after fluorophore modification, it was noted that MMNP@PEG
remained stable in 1× PBS for up to seven days (see Sections 3.5.1 and 3.5.2).
3.5. Fluorescence Functionalization
We compared twomethods ofMMNP functionalization with small organic fluorophores (Figure 5):
an in situ method in which the fluorescent molecules were mixed and incorporated with dopamine
during MMNP formation, and a post-functionalization method in which the fluorophores were added
onto purified MMNP@PEG. Both RA123 and RAB were used as model fluorophores. Both may
interact with polydopamine via pi–pi stacking, hydrogen bonding, or electrostatic interactions.
In addition, RA123 has a primary amine that may behave as a weak nucleophile to covalently
bind to oxidized quinones in polydopamine (Figure 5a). The predominant structure of RAB is
the fluorescent zwitterion, but a significant fraction of RAB also exists as a non-fluorescent lactone,
with Keq = [zwitterion]/[lactone] = 4.4 at 25
◦C in water (Figure 5b) [51]. The acidic cation of RAB has
pKa ≈ 3.2 but has been reported to increase up to 5.70 in the presence of microheterogeneities
in solution, such as the interfaces formed by surfactants, thus stabilizing it at higher pH than in
homogeneous solutions [52]. These molecules and their modes of binding may also be viewed as
models for the incorporation of other functionalities, such as chemotherapeutics.
3.5.1. In situ Incorporation
Melanin-mimetic nanoparticles were labeled in situ by growing MMNPs in 1 mg mL−1 DA
and 1:1 NaOH:DA in the presence of 50 µg mL−1 RA123 or RAB to prepare MMNP@RA123 or
MMNP@RAB, respectively (Figure 5c). These NPs were then modified with 5 kDa mPEG-SH to
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form MMNP@RA123@PEG and MMNP@RAB@PEG. In order to remove loosely bound dye, samples
were centrifugally filtered with extensive washing and then dialyzed for seven days in 1× PBS.
Approximately 90% of the physisorbed dye remaining after centrifugal filtration was released within
the first 24 h of dialysis (Supplementary Figure S7a). No aggregation was observed during immersion
in PBS for one week, indicating good steric stability imparted by the PEG coating.ȱŘŖŗŝǰȱŘǰȱŗŝȱ ŗŗȱȱŗş
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Figure 5. Approaches to synthesis of fluorescent MMNPs. (a) Structure of rhodamine
123 (RA123). (b) Structures of rhodamine B (RAB), including the fluorescent cationic acid,
non-fluorescent neutral lactone, and fluorescent zwitterionic structures. (c) In situ approach
and subsequent PEGylation: MMNP@RA123 and MMNP@RAB are first synthesized by
DA polymerization in the presence of RA123 or RAB. These fluorescent NPs are subsequently
PEGylated, forming MMNP@RA123@PEG and MMNP@RAB@PEG. (d) Post-functionalization
approach: MMNP@PEG@RA123 and MMNP@PEG@RAB are formed by treatment of MMNP@PEG
with RA123 or RAB in unbuffered ultrapure water or pH 8.5 buffer.
In the first step of MMNP growth in solution mixtures of DA and rhodamine, both UV–Vis
absorbance spectroscopy and fluorimetry provided evidence that RA123 and RAB were
successfully incorporated into the in situ labeled NPs and retained after centrifugal filtration
(Supplementary Figures S8 and S9a,b). The fluorescence emission peaks of MMNP@RA123@PEG
and MMNP@RAB@PEG were centered at 520 nm and 573 nm, respectively, similar to the free dyes,
and remained at those locations following extensive dialysis (Figure 6a,c). The 10 nm red-shift in the
MMNP@RA123@PEG absorbance peak (λabs = 510 nm) relative to free RA123 (λabs = 500 nm) may
indicate some dye aggregation in the NPs. After seven day dialysis in 1× PBS, the fluorescent
signal of a 25 µg mL−1 solution of MMNP@RA123@PEG approximately corresponds to that of
5.4 ng mL−1 free RA123, and the fluorescence of a 25 µg mL−1 solution of MMNP@RAB@PEG
approximately corresponds to that of 3.6 ng mL−1 free RAB. These in situ-modified NPs also have
full-width half-maximum (FWHM) of approximately 45 nm, which is two to three times narrower
than previously reported fluorescent polydopamine NP systems [26–28,30]. The broadband UV–Vis
absorbance pattern also verified that polydopamine growth could proceed in the presence of rhodamine
(Supplementary Figure S8). Furthermore, the largely negative zeta potentials of both MMNP@RA123
andMMNP@RABwere not significantly different from those ofMMNPswithout rhodamine, indicating
that the dyes were chiefly incorporated into the interior of the NPs (Supplementary Figure S10a).
Otherwise, the positively charged RA123 or various forms of RAB would have increased the zeta
potential significantly versus vs. MMNPs by masking the negative MMNP surface charge or by
reversing it, especially if the fluorophores segregated to the NP surface.
After PEGylation, zeta potential measurement provided evidence that grafting the polydopamine
NP surfaces with mPEG-SH was successful, as the zeta potentials became significantly less negative
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(−9.9± 1.4 mV forMMNP@RA123@PEG and−7.6± 1.9 mV forMMNP@RAB@PEG, vs. −34.4± 0.8 mV
for MMNP@RA123 and−39.3± 1.3 mV for MMNP@RAB; Supplementary Figure S10a). However, a high
polydispersity interfered with quantitative use of DLS data (Supplementary Figure S10b), and an increase
in Dh following PEGylation could not be confirmed. In fact, TEM shows that these NPs were more
polydisperse and less well-defined than MMNPs grown without dye (Figure 6b,d). It is possible
that a lower level of rhodamine incorporation could restore normal MMNP growth and this could
be worth pursuing in future work given the encouraging fluorescence profile, colloidal stability,
and straightforward synthesis of the in situ modified NPs.
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Figure 6. Fluorescence emission spectra and TEM images of in situ labeled MMNP@RA123 and
MMNP@RAB. (a) Fluorescent emission spectra (λex = 500 nm) of MMNP@RA123@PEG after seven day
dialysis in 1× phosphate-buffered saline (PBS), rhodamine 123, and MMNP@PEG. (b) TEM image of
MMNP@RAB. (c) Fluorescent emission spectra (λex = 555 nm) of MMNP@RAB@PEG after seven day
dialysis in 1× PBS, rhodamine B, and MMNP@PEG. (d) TEM image of MMNP@RA123.
3.5.2. Post-Functionalization
MMNP@PEG (40 µg mL−1; Dh = 71.5 ± 0.6 nm) were post-functionalized by incubating in
50 µg mL−1 RA123 or RAB dye to form MMNP@PEG@RA123 or MMNP@PEG@RAB, respectively
(Figure 5d). Two solution conditions were tested: functionalization in UP water and in buffer at pH 8.5.
Both RA123 and RABmaymodify the free polydopamine surface remaining in between the PEG chains
via non-covalent interactions such as pi–pi stacking or hydrogen bonding. The positive charge of RA123
could also promote more electrostatic attraction to the negatively charged polydopamine surface
than RAB. The primary amine on the RA123 could undergo Michael addition for covalent binding to
polydopamine especially at the pH 8.5 basic condition as well [50], although this coupling may not be
prominent, since the aromatic primary amine is a weak nucleophile [53].
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Rhodamine functionalization was first confirmed by the appearance of prominent absorption
peaks in UV–Vis spectra and fluorescence emission spectra taken directly following extensive
centrifugal filtration to remove the dissolved free dye in the solution used for functionalization
(Supplementary Figures S9c,d and S11). The red-shifted absorbance peaks on MMNP@PEG@RA123
(λabs = 520 nm) vs. free RA123 (λabs = 500 nm) indicate that the RA123 has aggregated on the
NP surface, potentially due to high loading. No obvious differences were noted between samples
modified in UP water or at pH 8.5. Moreover, both MMNP@PEG@RAB and MMNP@PEG@RA123
have significantly higher zeta potentials than MMNP@PEG (Figure 7a), further indicating coverage
of and binding to the polydopamine NP surface underlying the PEG brush. The finding that the
zeta potentials for all of the post-functionalized NPs were similar may indicate that the cationic form
of RAB is stabilized at the negatively charged MMNP surface, as observed in microheterogeneous
solutions containing surfactant micelles [52]. Dynamic light scattering measurements show that the
NP diameter generally did not increase after dye functionalization, except for a <10% increase for
MMNP@PEG@RAB modified at pH 8.5 (Figure 7b). It is thus unlikely that polydopamine growth or
NP aggregation occurred during fluorophore loading.
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Figure 7. Fluorescence, hydrodynamic diameter, and zeta potential of rhodamine post-functionalized
MMNP@PEG. (a) Zeta potentials and (b) hydrodynamic diameters of rhodamine post-functionalized
MMNP@PEG samples prepared in water or at pH 8.5 vs. unmodified MMNPs and MMNP@PEG.
Groups not sharing symbols have significantly different values (p < 0.05). (c) Fluorescence emission
spectra (λex = 500 nm) of 25 µgmL
−1 samples ofMMNP@PEG before and after modificationwith RA123
in water or at pH 8.5 followed by serial dialysis in ultrapure (UP) water for 72 h and 1× PBS for 72 h.
Emission spectrum of RA123 was taken at 10 ngmL−1. (d) Fluorescence emission spectra (λex = 555 nm)
of 25 µg mL−1 samples of MMNP@PEG before and after modification with RAB in water or at pH 8.5
followed by serial dialysis in UP water for 72 h and 1× PBS for 72 h. Emission spectrum of RAB was
taken at 10 ng mL−1.
Biomimetics 2017, 2, 17 14 of 19
To ensure that the fluorescent emission of MMNP@PEG@RA123 and MMNP@PEG@RAB was
due to the fluorophores bound to the MMNPs and that this emission would be stable, additional
dialysis was performed after centrifugal filtration—72 h in UP water followed by a further 72 h in
1× PBS—to remove dye molecules that could be desorbed from the MMNPs. The dialysis process
was successful in removing this loosely bound fraction (over 80% of removable fraction of dyes
was released within the first 24 h of the first UP water dialysis) (Supplementary Figure S7b,c).
Although measurements of the emission levels during dialysis do show that a large portion
of the initially measured fluorescence was due to loosely bound dyes that desorb from the
NP surface (Supplementary Figure S7b,c), the fluorescence of MMNP@PEG@RA123 was still detectable
(Figure 7c). The emission peaks of MMNP@PEG@RA123 centered at λem = 520–524 nm, which are
essentially unchanged from the free dye. The fluorescence remaining in 25 µg mL−1 samples of
MMNP@PEG@RA123 corresponded to 2.9 ng mL−1 RA123 for the pH 8.5 modification condition and
8.3 ng mL−1 RA123 for the UP water modification condition. Thus, the RA123 remained strongly
bound to the MMNP@PEG@RA123 surface, and the pH 8.5 condition did not enhance interactions
between aromatic amines on RA123 and polydopamine vs. UP water.
On the other hand, no emission peaks are observed in dialyzed MMNP@PEG@RAB samples
(Figure 7d). Taken together with zeta potential results, which suggest the presence of the acidic
cation of RAB at the MMNP surface, the almost total removal of RAB after dialysis also suggests
an electrostatic binding mechanism: During dialysis, the bound fluorescent RAB cation may equilibrate
with the non-fluorescent lactone and fluorescent zwitterionic RAB forms, which may subsequently
desorb from the NP surface due to less electrostatic attraction to polydopamine.
We also observed that during the dialysis process, more RA123 was released in the first UP water
dialysis step for samples prepared at pH 8.5 than in UP water. This result indicates that covalent bonding
is not preferred at pH 8.5 and that electrostatic attraction between RA123 and polydopamine may be
the preferred mechanism of RA123 loading onto the MMNP surface. Regardless, the fluorescence of the
MMNP@PEG@RA123 after extensive dialysis also shows that this physical binding is sufficient to
obtain stable fluorescent NPs. More RA123 was released from samples prepared in UP water in the
second dialysis step in 1× PBS. The origin of this effect is unclear. Nevertheless, the level of RA123
fluorescence retained on NPs functionalized in UP water was significantly higher, and this approach
was used to generate MMNP@PEG@RA123 for cell work.
3.6. In Vitro Cytocompatibility of MMNP@PEG and Imaging of MMNP@PEG@RA123
The viability of NIH/3T3 fibroblasts incubated in media loaded with MMNP@PEGwas evaluated.
A range of NPs with Dh = 42 nm to 146 nm were tested (the diameters refer to the values measured
for the specific batch of NPs used for each viability assay rather than the averages shown in Figure 2).
No toxicity was observed over a duration of 24 h at all tested concentrations (1–100 µgmL−1; Figure 8a).
In fact, some increase in relative cell viability was observed for cells treated with MMNP@PEGs,
most notably for the smallest 42 nm diameter tested (up to 40% higher). This effect was previously
observed in HeLa cells at 6–75 µg mL−1 treatments, but not in 4T1 cells [13,23]. It is possible that
this dose-dependent effect stems from the known antioxidant capacity of MMNPs [13], which may
alter cellular proliferation by limiting oxidative stress in some cells. Finally, confocal microscopy
was used to characterize the cell uptake of MMNP@PEG@RA123. Figure 8b shows a representative
three-dimensional (3D) z-stack composite reconstruction of the NIH/3T3 fibroblasts treated with
both Hoechst dye and MMNP@PEG@RA123 (separately imaged with 760 nm two-photon and
regular 488 nm excitation, respectively). After 24 h incubation, the fluorescence associated with the
MMNP@PEG@RA123 could be clearly observed, even at the relatively low incubation concentration of
20 µg mL−1. Additional z-stack confocal images and 3D reconstructions of treated cells vs. untreated
control cells confirmed that the observed fluorescence was located within the cells, indicating MMNP
internalization (Figure 8b and Supplementary Figures S12–S16). Co-staining the cells with the
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in the perinuclear region—they were excluded from both the cell nuclei and the filapodia regions.
It was also observed that MMNP@PEG@RA123 have a punctate distribution within cells. From these
confocal microscopy images, it is evident that MMNP@PEG@RA123 is sufficiently stable to be utilized
in high-resolution, multimodal cell imaging.ȱŘŖŗŝǰȱŘǰȱŗŝȱ ŗśȱȱŗş
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Figure 8. In vitro investigation of MMNP-cell interactions. (a) MMNP cytocompatibility with
NIH/3T3 fibroblasts as measured by neutral red uptake viability assay. Error bars represent standard
errors of triplicate experiments. (b) Representative confocal microscopy three-dimensional (3D)
z-stack reconstruction image of Hoechst-stained NIH/3T3 fibroblasts treated with 20 µg mL−1
MMNP@PEG@RA123. Hoechst stain (blue) and rhodamine fluorescence (red/pink) are shown here;
Scale bar: 20 µm between gridlines.
4. Conclusions
We have demonstrated spherical MMNPs labeled with fluorescent dyes with controlled diameters.
Careful measurements based on multiple independent batches of NP preparation (up to 19) showed
how adjustment of DA concentration and NaOH:DA ratio in MMNP synthesis could be used to
achieve fine control of batch mean MMNP diameter in the sub-100 nm range. Similarly, our conditions
for MMNP PEGylation produced particles with a high degree of stability in both 1× PBS and in cell
culture media. Melanin-mimetic nanoparticle formation was shown to follow an autoxidation route,
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and the similarities of MMNPs with polydopamine and melanin in terms of chemical identity and
surface charge were shown by UV–Vis absorption, zeta potential, and XPS analysis. No cytotoxicity
was observed over the entire range of diameters from ≈40 to 150 nm tested.
We also compared two approaches of loading MMNPs with aromatic fluorescent dyes—in situ
dye loading during MMNP formation and post-functionalization after MMNP formation and
PEGylation. The fluorescence spectra of MMNPs obtained using both protocols produced emission
peak widths ≈40 nm FWHM, similar to the free dye and less than half that of previous reports of
fluorescent polydopamine NPs. The in situ approach, however, modified the shape of the MMNPs,
but post-functionalization could be used to produce spherical MMNPs with stable fluorescence suitable
for high-resolution multimodal confocal live cell imaging.
The reproducible diameter control and facile methodologies for functionalizing and loading
the MMNPs are highly applicable to fundamental studies and further refinement of organic NP–cell
interactions, such as size-dependent cellular uptake and intracellular trafficking using targeting
moieties. The stable and spectrally narrow fluorescence measured indicate that our protocol could
be beneficial for incorporating dyes into MMNPs (or other polydopamine matrices) for multimodal
imaging studies, or for delivery of therapeutic molecules with weak interactions to MMNPs.
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